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Abstract 
 
In “Global health 2035: a world converging within a generation,” The Lancet 
Commission on Investing in Health (CIH) adds the value of increased life expectancy to 
the value of growth in gross domestic product (GDP) when assessing national well-being. 
To value changes in life expectancy, the CIH relies on several strong assumptions to 
bridge gaps in the empirical research. It finds that the value of a life year (VLY) averages 
2.3 times GDP per capita for low- and middle-income countries (LMICs) assuming the 
changes in life expectancy they experienced from 2000 to 2011 are permanent. We 
investigate the sensitivity of this estimate to the underlying assumptions, including the 
effects of income, age, and life expectancy, and the sequencing of the calculations. We 
find that reasonable alternative assumptions regarding the effects of income, age, and life 
expectancy may reduce the VLY estimates to 0.2 to 2.1 times GDP per capita for LMICs. 
Removing the reduction for young children increases the VLY, while reversing the 
sequencing of the calculations reduces the VLY. 
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Introduction 
 
In its 2013 report, “Global health 2035: a world converging within a generation,” The 
Lancet Commission on Investing in Health (CIH) recommended the use of a “full 
income” approach to incorporate the benefits of health improvements into national 
accounts.1 Under this approach, the value of changes in life expectancy are added to the 
value of changes in gross domestic product (GDP) to capture the effects of health 
improvements at the population level.  
 
To support this approach, prominent members of the Commission, including economists 
Dean Jamison, Lawrence Summers, and Kenneth Arrow, developed an innovative 
method for estimating the value of an increase in population life expectancy and 
translating the results into an average value of a life year (VLY).2 They adjust a U.S. 
estimate of the value of mortality risk reduction, assuming this value is proportional to 
GDP per capita and to remaining life expectancy. In their main result, they decrease the 
value for children aged 0 through 4  by 50 percent, then divide the total by the life 
expectancy gain to estimate VLY. This VLY is 2.3 times 2000 GDP per capita for life 
expectancy gains experienced by low- and middle-income countries (LMICs) from 2000 
to 2011, assuming the gain is permanent, or 3.0 times GDP per capita without the 
reduction for young children. The CIH also reports the value of life expectancy gains for 
other country groups and time periods using the same approach, and applies the results to 
estimate the benefits of the interventions it recommends. 
 
This VLY is within the range of the illustrative estimates of 1.0 to 3.0 times GDP per 
capita referenced by the 2001 Commission on Macroeconomics in Health (CMH), 
currently used as cost-effectiveness thresholds in the World Health Organization’s 
Choosing Interventions that are Cost-Effective program and elsewhere.3,4 The CMH 
multipliers were intended as rough estimates of the value an average individual might 
place on an incremental change in life expectancy.5 In contrast, the CIH multiplier is 
based on a specific historical gain. 
 
The CIH faced many challenges in developing its approach. We examine the sensitivity 
of the 2.3 times GDP per capita estimate highlighted in its main report to changes in the 
parameter values.1, p. 1913 Our goal is to investigate the effects of plausible alternative 
assumptions and to provide insights into the uncertainties in the results as well as the 
issues that arise in tailoring the approach for application elsewhere. 
 
General Framework 
 
Conceptually, the CIH approach is intended to reflect the value that members of a 
population place on specific changes in their own life expectancies. In this context, 
money is not of interest per se: it measures the extent to which individuals are willing to 
trade consumption of other goods and services for a life expectancy increase. Because 
these preferences are likely to vary across individuals and societies, ideally such analyses 
would rely on estimates from the affected population. However, due to gaps and 
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inconsistencies in the empirical research, these values must be extrapolated from studies 
of other populations that differ in significant respects. 
 
The CIH starts with an estimate of the value per statistical life (VSL), which represents a 
population average of individuals’ marginal rates of substitution between money and 
mortality risk in a defined time period.6 Conventionally, VSL is estimated by dividing 
empirical estimates of individual willingness to pay for a small change in one’s own risk 
by the risk change.  
 
The associated value per statistical life year (VSLY) could be estimated directly by 
researching the values individuals place on an increase in life expectancy, but few 
empirical studies exist. Instead, VSLY is usually estimated as a constant, by dividing 
average VSL by the remaining (discounted) life expectancy for the average individual.7,8 
Valuing current mortality risk as the product of a constant VSLY and remaining life 
expectancy yields values that decrease with age.  
 
The CIH also derives a value  per life year from a VSL estimate, but uses a different 
approach, as described in detail in the Methods section. The result is the average value of 
a specified population increase in life expectancy. Analysts who are interested in 
applying the CIH approach would need to follow the same steps to calculate the VLY 
associated with a particular policy. We follow the CIH practice and use the term “VLY” 
to distinguish their population-based quantity from the conventional VSLY.  
 
Monetary values for improved survival are expected to vary with characteristics of the 
affected population and the mortality risks. The effects of many characteristics are not 
well-understood; there are significant inconsistencies and gaps in the available research 
even for high-income countries.9,10 In its analysis, the CIH focuses on the variation 
associated with income and age-specific life expectancy. 
 
Most VSL studies address high-income countries.11,12,13 Research on the relationship 
between income and VSL generally confirms that VSL increases with income, as 
anticipated. However, the proportional change in VSL in response to a proportional 
change in income (i.e., its income elasticity) is uncertain. While theory and empirical 
studies generally support elasticities greater than one, some studies report elasticities as 
high as two or three while others report values less than one.14 Income elasticity is of 
particular importance when extrapolating from very high to very low income countries 
because the range of potential elasticities may affect the resulting VSL by orders of 
magnitude. Theoretical models suggest VSL will exceed the present value of future 
income or consumption because VSL reflects non-monetary  benefits of living in addition 
to the monetary value of consumption and future earnings. Thus the income-adjusted 
VSL should not fall below the present value of income or consumption.14  
 
The theoretical and empirical evidence on the relationship between VSL and age or life 
expectancy is inconsistent, and generally does not support the hypothesis that VSL is 
proportional to (discounted) life expectancy nor the application of a constant VSLY.15,16 
Some studies find an inverse-U relationship between VSL and age for working-age 
  
4 
adults, consistent with the prediction of life-cycle models.17,18,19 Other studies, which 
include adults older than working age, find that values may decrease or remain constant 
with age.20,21 
 
Much of the research in higher-income countries suggests that adults value reducing risks 
to children more than to themselves.22,23,24 The CIH posits, however, that particularly for 
countries with relatively low life expectancies, where much of the life expectancy gain 
results from decreased infant and child mortality, “[i]t is plausible that many societies and 
individuals will value reducing death rates at very young ages less than reducing death 
rates among, say, 25 year olds.”(2, p. 5) The CIH notes that empirical evidence supporting 
such lower values is “limited.” 
 
Methods 
 
The CIH faced two major challenges. First, most empirical estimates of the value of 
mortality risk reductions focus on high-income countries, while the CIH was interested in 
values for LMICs. Second, the available values are for a reduction in current mortality 
risk, while the CIH was interested in the value of life extension.  
 
The CIH approach to the first challenge is relatively straightforward. They begin by 
dividing a VSL estimate by 10,000 to yield the value of a standardized mortality unit 
(VSMU) in 2011 dollars. They use “SMU” to refer to a 1 in 10,000 risk reduction for the 
current year and “VSMU” to refer to individual willingness to pay for this risk change. 
They use this terminology in part because the VSL concept is widely misunderstood.25 It 
is not the value of saving a life with certainty; rather the VSL is derived from the value 
that an individual places on small changes in his or her own mortality risk, such as a 1 in 
10,000 reduction.  
 
The CIH states that it is reasonable to assume that the U.S. VSMU was 1.8 percent of 
U.S. GDP per capita in the year 2000, and that this ratio is constant across time and 
populations. In other words, they assume an income elasticity of 1.0: a one percent 
change in GDP per capita is associated with a one percent change in VSL and VSMU. 
For LMICs, the CIH uses the average of 2000 and 2011 GDP per capita, estimated as 
$2,718 and $4,201 respectively. 
 
The CIH approach to the second challenge is more complex, and differs from the 
approaches commonly used. To estimate the value of a change in population life 
expectancy, they associate that change with a set of age-specific changes in current 
mortality risk valued using a set of age-specific VSMUs. To derive these VSMUs, the 
CIH requires data on population survival rates for each year of age, which are not 
available for most LMICs. They instead rely on Japanese life tables which reflect a 
similar change in average life expectancy at birth as found in the LMICs over the period 
of concern, noting that Japan provides “good historical data.” More specifically, they 
estimate that life expectancy at birth across all LMICs in 2000 and 2011 was 65 and 68 
years, respectively. They find that Japanese life tables for 1955 and 1961 reflect a similar 
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life expectancy at birth. CIH then uses the corresponding Japanese age-specific mortality 
rates to calculate changes in age-specific mortality risk for LMICs. 
 
In its calculations, the CIH uses age groups (generally 10 year increments, although 5-
year increments are used for ages 0 through 9 and a single category is used for age 80 and 
higher), applying values for the midpoint of each age group from the life tables. They 
assume that the U.S. VSMU reflects the value for an individual aged 35, who has 45 
years of remaining life expectancy, and anchor the income-adjusted values for other 
countries at age 35. This anchor VSMU is then adjusted for other ages in proportion to 
remaining life expectancy, estimated using the 1958 (midpoint of 1955 and 1961) life 
table for Japan.  
 
CIH calculates the present value of the change in life expectancy by summing, over all 
age groups, the product of the age-specific VSMU, the age-specific risk change, and the 
fraction of the LMIC population in that age group in 2005 (midpoint of 2000 and 2011). 
Assuming the increase in life expectancy is permanent (i.e., the mortality risk reduction is 
sustained across all future generations), CIH calculates the present value of an infinite 
stream of annual values using a 3 percent annual discount rate. Dividing by the increase 
in life expectancy yields the VLY. The CIH does not account for the age distribution shift 
that results from the change in mortality rates. 
 
Prior to calculating the VLY, the CIH reduces the VSMUs for children aged 0 through 4 
by 50 percent, to reflect the hypothesis that the affected populations place a lower value 
on these risk reductions than on those that occur at older ages. Elsewhere in its analysis, 
CIH tests the effects of eliminating this adjustment, of excluding children under 10, and 
of excluding adults older than 70. 
 
In our calculations, we rely on data from spreadsheets provided by CIH staff, which 
include more detail but occasionally differ from the description in their report.2 (It 
appears that the CIH intended to subtract health expenditures from the GDP per capita 
estimates, but does not do so consistently. However, this inconsistency has little effect on 
resulting VLY.) Like the CIH, we use income as a shorthand for GDP per capita, 
discount future values at 3 percent per year, calculate the value of risk reductions using 
their estimates of the average of 2000 and 2011 GDP per capita, and calculate the VLY 
multiplier based on their estimate of 2000 GDP per capita. CIH references the World 
Bank’s 2013 World Development Indicators report as the source of the country 
classification used to define LMICs and the GDP estimates.26 
 
We explore the key assumptions listed in Table 1, basing our sensitivity analysis on 
plausible alternatives described in more detail below. Of these assumptions, we expect 
that the range of income elasticities will have the largest effect. The appropriate elasticity 
is highly uncertain, and small changes in the elasticity can alter the results by orders of 
magnitude.  
 
 
Table 1. Assumptions explored in sensitivity analysis  
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CIH Main Case Sensitivity Analysis 
1. Assume VSMU is 1.8 percent of 
GDP per capita. 
1. Assume VSMU is 1.7 percent of GDP 
per capita. 
2. Assume an income elasticity of 1.0. 2(a,b). Assume an income elasticity of 1.5 
or 2.0. 
3(a). Convert increases in life 
expectancy to changes in age-specific 
mortality rates using Japanese life 
tables. 
3(a). Replace Japanese life tables with 
Bulgarian life tables.  
3(b). Adjust the VSMU for age by the 
ratio of the remaining life expectancy 
at each age and at the anchor age of 
35, which is the age at which U.S. life 
expectancy is 45 years.  
3(b). Replace the anchor age of 35 with 
the age at which remaining Bulgarian life 
expectancy is 45 years (age 25). 
 
Sensitivity Analysis Results  
 
We change each assumption individually then examine their joint effect. In addition, we 
test the effect of re-ordering the steps, calculating the VLY for the U.S. then adjusting for 
income. We do not test the effects of altering the assumption that changes in value are 
proportional to changes in life expectancy, although this assumption is inconsistent with 
much of the VSL research summarized above. 
 
Assumption 1: VSMU  
In a recent criteria-driven literature review, the authors report a central U.S. VSL estimate 
of $9 million, expressed in 2013 dollars at 2013 income levels.9 Dividing by 10,000 
yields a VSMU of $900; 1.7 percent of 2013 U.S. GDP per capita in 2013 dollars. This 
small reduction decreases the LMIC VLY from 2.3 to 2.1 GDP per capita. 
 
Assumption 2: Income elasticity 
We apply income elasticities of 1.5 and 2.0 to illustrate the effects of larger elasticities 
using Equation (1), based on the average of 2000 and 2011 U.S. GDP per capita ($44,781 
and $48,112 respectively) from the CIH spreadsheets.14 
  VSMULMICs = VSMUUS  × �GDP per capita LMICs GDP per capita US� �Income Elasticity   
(1) 
 
Because changing the elasticity has an exponential effect, the range of elasticities found 
in the literature significantly affects the estimates. Increasing income elasticity to 1.5 and 
2.0 decreases the LMIC VLY to 0.6 and 0.2 GDP per capita, respectively, violating the 
expectation that individuals will value an increase in life expectancy by an amount that 
exceeds what they would earn over the same time period. 
 
Assumption 3: Life tables and anchor age 
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We replace the Japanese life tables with life tables from a LMIC that yields a similar 
change in life expectancy but with a different pattern of age-specific mortality. We 
selected the Bulgarian life tables from 1955 and 1958 as an illustrative example because 
they are from the same data source as the Japanese life tables; this source includes life 
tables for only one other LMIC (Ukraine).27 We also consider the effect of changing the 
anchor age from 35 years to the age at which remaining life expectancy is 45 years (as 
assumed by the CIH for the U.S.). For Bulgaria, this is age 25 using the midpoint (1956 
or 1957) life table. Changing the life tables while keeping the anchor age at 35 reduces 
the GDP per capita multiplier to 1.7. Moving the anchor to age 25 leads to a further 
decline to 1.4.  
 
This analysis suggests that the VLY is sensitive to the age distribution of the survival 
gains. Improvements in Bulgarian survival rates between 1955 and 1958 were more 
concentrated in younger age groups than in Japan. We illustrate the distribution in Figure 
1, which calculates the change in age-specific SMUs using each set of life tables and 
weights the results by the LMIC population within each age group. 
 
[Figure 1 about here] 
 
Combined effect: 
We combine a VSMU of 1.7 percent of GDP per capita, an income elasticity of 1.5, and 
Bulgarian life tables anchored at 25 years of age, and find the VLY decreases to 0.4 times 
GDP per capita. 
 
Repeating each analysis without the reduction for ages 0 through 4 used in the original 
CIH estimates increases the estimates in each case, as expected. Table 2 summarizes 
these results. 
 
Table 2. Results with alternative assumptions 
Sensitivity analysis 
LMIC VLY as multiplier of GDP per 
capita 
With 50% 
reduction for ages 
0 through 4 
Without reduction 
for ages 0 through 4 
Original CIH estimate 2.3 3.0 
(1) VSMU = 1.7 percent of GDP per capita 2.1 2.8 
(2a) Income elasticity = 1.5 0.6 0.8 
(2b) Income elasticity = 2.0 0.2 0.2 
(3a) Bulgarian life table, anchoring at age 35 1.7 2.9 
(3b) Bulgarian life table, anchoring at age 25 1.4 2.4 
Combination: VSMU = 1.7 percent GDP per 
capita, income elasticity = 1.5, Bulgarian life 
table anchoring at age 25 
0.4 0.6 
 
Alternative sequencing: 
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The CIH adjusts the VSMU for income then calculates the VLY. We reverse the order, 
calculating VLY for the U.S. (using U.S. life tables from the same data source27) for the 
same period (2000 and 2011), then adjusting for income based on the average of the 
LMIC 2000 and 2011 values. Without reducing the values for young children, we find 
that the VLYs for LMICs range from 0.1 to 2.0 GDP per capita, depending on the income 
elasticity (Table 3). 
 
As in some of our earlier calculations, the resulting VLY is less than GDP per capita for 
LMICs when income elasticities of 1.5 and 2.0 are applied, contrary to theoretical 
expectations. Thus we explore the effect of using GDP per capita as a lower bound. To be 
consistent with the CIH approach, we set the lower bound at the average of 2000 and 
2011 GDP per capita, and express the VLY as a multiplier of 2000 GDP per capita. We 
find the multiplier becomes 1.3 to 2.0, depending on the income elasticity. Using the 
average of 2000 and 2011 GDP per capita as the base would decrease the multiplier.  
 
Table 3. Results with alternative sequencing  
Sensitivity analysis starting 
with a U.S. VLY 
LMIC VLY as multiplier of GDP per capita 
Without reduction for ages 0 through 4 
Without income floor With income floor 
(a) Income elasticity = 1.0 2.0 2.0 
(b) Income elasticity = 1.5 0.5 1.3 
(c) Income elasticity = 2.0 0.1 1.3 
 
Discussion 
 
The CIH methodology is fundamentally different from the traditional VSLY approach. 
Rather than deriving a VSLY from a VSL estimate then applying it to predicted life 
expectancy gains, the CIH estimates the value of age-specific changes in risks, weights 
by the population age distribution, then divides by the population life expectancy gain 
(assuming it is permanent) to calculate the average VLY. 
 
For example, using the CIH methodology, the VLY for the change in U.S. life 
expectancy from 2000 to 2011 is roughly $68,000. Using the conventional approach to 
calculate a VSLY from a VSL yields a much larger value. The CIH assumptions yield a 
U.S. VSL of $7.5 million (180 times the average of 2000 and 2011 U.S. GDP per capita). 
Dividing by an average remaining life expectancy of 45 years yields a VSLY of 
$170,000, or $300,000 if future years are discounted using the CIH rate of 3 percent 
annually. Thus the choice of approach may significantly affect the analytic conclusions, 
but without more empirical research it is difficult to determine which approach is most 
appropriate. Both have significant limitations and illustrate the enormous challenges that 
analysts face, given the inconsistencies and gaps in the research literature and the many 
ways in which they can be addressed. 
 
The CIH approach is designed to compare the value of the historical life expectancy gains 
over time, across countries and regions, or across interventions. The resulting VLY 
estimate is an analytic output; it is not a value intended to be used as an input to value life 
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expectancy gains in other settings. The estimates underlying the average VLY vary by 
country and age group, and reflect survival gains over a particular time period. Thus the 
2.3 times GDP per capita value should not be directly applied in other settings. 
 
Instead, analysts interested in applying the CIH approach would need to follow the same 
steps in their calculations. We find that the CIH estimate of the average VLY is very 
sensitive to the underlying assumptions, ranging from 0.2 to 3.0 times GDP per capita. 
Thus analysts should examine the inputs and assumptions and adapt them to their setting. 
Note, however, that multipliers less than 1.0 times GDP per capita (for the same year) 
seem implausible, given that we expect the VLY(as well as the VSLY) to exceed annual 
income. Thus GDP per capita should be used as a lower bound. Our results also suggest 
that analysts should explicitly address uncertainties in these values and discuss the 
implications for decision-making. 
 
More specifically, as illustrated in our sensitivity analysis, the value of changes in life 
expectancy in LMICs is highly sensitive to the income elasticity used. However, our 
reviews of the literature suggest that more work is needed to determine the appropriate 
elasticity.14 In the interim, analysts should test the sensitivity of their conclusions to a 
reasonable range of elasticities. In some cases, they are likely to find that an intervention 
is cost-beneficial, or is not cost-beneficial, regardless of the elasticity estimate; in other 
cases, the conclusions may be more uncertain. Highlighting such findings will aid 
decision-makers and other stakeholders in understanding the degree to which they should 
have confidence in the results. 
 
The relationship of the VLY or VSLY to age or life expectancy is more complex and 
more difficult to resolve, raising both empirical issues (whether individuals’ willingness 
to pay for their own risk reductions varies by age) and normative issues (how society 
should value risk reductions depending on the age of those affected). As discussed 
earlier, the available VSL research is not conclusive, but suggests that adults in high-
income countries may place higher values on risk reductions that accrue to children, that 
adult values for their own risk reductions over their working years may follow an inverse-
U pattern, and that the values held by older adults may remain constant or decrease with 
age. It is unclear whether similar patterns are likely to hold in LMICs, given cultural and 
other differences.  
 
Both the CIH VLY approach and the standard VSLY approach simplify this age 
relationship. In its main results, the CIH down-weights the values for young children, but 
otherwise both the VLY and the VSLY approach lead to total values that decrease with 
age. More work is needed to examine the empirical and normative concerns that underlie 
these age adjustments. In the interim, analysts should be clear about both the rationale for 
their approach and the extent to which it is supported by available research, and discuss 
the implications of related uncertainties. 
  
Our sensitivity analysis is not intended to be a comprehensive assessment of the effects of 
the CIH assumptions, nor do we intend to endorse or propose any particular approach. 
The limited and inconsistent empirical research means that there are numerous ways in 
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with these values can be estimated. More studies are needed to estimate key inputs such 
as the appropriate VSL and the relationship between VSL, age, life expectancy, and 
income.  
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Figure 1. Figure 1. Distribution of the changes in the standard mortality unit by age group 
in Japan (between 1955 and 1961) and Bulgaria (between 1955 and 1958), weighted by 
the population density of LMICs in 2005.  
 
 
